[Assessment of the exhaled nitric oxide measurement for asthma management]

Guzina I, David DJ
Record ID 32018012119
French
Original Title: Mesure de la fraction expirée du monoxyde d’azote (FeNO) pour l’ajustement des traitements de l’asthme
Authors' objectives: 1) Assess the clinical utility of adding FeNO measurement to the current monitoring strategy of asthmatic patients (including the clinical examination, the use of standardized asthma control questionnaires, respiratory function tests and the reversibility test under bronchodilator); 2) Describe the technical conditions to enable a successful completion of the measure 3) Advise on the opportunity to have this measure covered by the Social Security
Authors' recommendations: Given the results of this assessment, it is not possible to conclude on the added value of including the FeNO measurement as an additional measure to the current asthma treatement adjustement strategy, neither for adult or pediatric patients.
Authors' methods: 1) Critical analysis of scientific literature identified after systematic research and selected on explicit criteria (defined in the PICOTS grids) 2) Consultation of professionals and patients via a) a meeting of external experts within a working group, and b) staleholder (representatives of professional organizations and patient associations) consultation on the report . 3) Compilation of these different elements in a HTA report, examined by the Commission for the Evaluation of Diagnostic, Prognostic and Predictive Health Technologies and ultimately validated by the HAS Board.
Authors' identified further research: HAS encourages to pursue studies on FeNO measurement in order to obtain data allowing to objectify and measure the impact of this measure on patients, as well as in order to define the thresholds for the interpretations of the measure, within the framework of practices similar to French practice. These studies should focus on the use of FeNO measurement as a complementary tool for the adjustment (discontinuation) of monoclonal antibodies in severe asthmatics (taking into account the total absence of studies in this population currently) as well as, with regard to the adjustment of corticosteroid therapy , as a complementary tool to help clinicians in situations of doubt in patients with uncontrolled or severe asthma.
Details
Project Status: Completed
URL for project: https://www.has-sante.fr/jcms/p_3331921/fr/mesure-de-la-fraction-expiree-du-monoxyde-d-azote-feno-pour-l-ajustement-du-traitement-de-l-asthme
URL for protocol: https://www.has-sante.fr/jcms/p_3331919/fr/mesure-de-la-fraction-expiree-du-monoxyde-d-azote-feno-pour-l-ajustement-du-traitement-de-l-asthme-note-de-cadrage
Year Published: 2023
URL for published report: https://www.has-sante.fr/jcms/p_3444709/fr/mesure-de-la-fraction-expiree-du-monoxyde-d-azote-feno-pour-l-ajustement-du-traitement-de-l-asthme-rapport-d-evaluation
Requestor: Asthma patients and their caregivers; healthcare professionals involved in asthma management ; nts with asthma; decision-makers in charge of reimbursement decisions and those in charge of the organization of care.
URL for additional information: https://www.has-sante.fr/jcms/p_3444710/fr/mesure-de-la-fraction-expiree-du-monoxyde-d-azote-feno-pour-l-ajustement-du-traitement-de-l-asthme-annexes-au-rapport-d-evaluation
English language abstract: There is no English language summary available
Publication Type: Mini HTA
Country: France
MeSH Terms
  • Asthma
  • Fractional Exhaled Nitric Oxide Testing
  • Nitric Oxide
  • Breath Tests
Keywords
  • asthma
  • nitric oxide
  • biomarkers
  • breath tests
  • fractional exhaled nitric oxide
Contact
Organisation Name: Haute Autorité de Santé
Contact Address: 2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name: has.seap.secretariat@has-sante.fr
Contact Email: has.seap.secretariat@has-sante.fr
Copyright: <p>Haute Autorite de Sante/French National Authority for Health (HAS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.